Alexandra Gerlach, Content Producer

Follow-up data reveal 10-year impact of ibrutinib in treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).

Perinatal depression increases the risk of cardiovascular disease in women.

Tepylute is a ready-to-dilute, injectable formula that reduces preparation time and enable dosing accuracy.

Antibody drug conjugate TUB-040 demonstrated superior biophysical properties for treating platinum-resistant ovarian cancer.

A report from the Milken Institute highlights the crucial role of pharmacists in advancing food is medicine care.

A biologics license application (BLA) for patritumab deruxtecan receives complete response letter due to inspection findings at third-party manufacturer.

The supplemental new drug application (sNDA) for brexpiprazole is accepted by the FDA for treatment of patients with post-traumatic stress disorder (PTSD).

Adagrasib receives accelerated approval for patients with previously treated KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC).

Adopting the Planetary Health Diet may reduce overall risk of chronic disease and premature death.

Study shows that orange peel extract may reduce risk of heart disease and adverse cardiovascular events.

Secondhand exposure to e-cigarette smoke may increase risk of pediatric atopic dermatitis in children.

The FDA approved blinatumomab for treatment of patients with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

Zanubrutinib shows potential in treating patients with treatment-naïve high-risk chronic lymphocytic leukemia and/or small lymphocytic lymphoma with del(17p) and/or TP53 mutation.

Trametinib may become an alternative treatment to hematopoietic stem cell transplantation in patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML).

Amplification of chromosome 1q is associated with poorer treatment outcomes for patients with relapsed/refractory and newly diagnosed multiple myeloma.

Reducing sodium intake is associated with decreased risk of atopic dermatitis (AD) and flares.

Eating a poor diet might lead to structural brain changes that cause the development of common mental disorders (CMD).

Continuous glucose monitoring systems offer timely biofeedback for patients with type 2 diabetes.

Research has found that increased consumption of sugar alcohols, like xylitol, may increase risk of cardiovascular events.

Osimertinib demonstrates improved progression-free survival for stage 3 epidermal growth factor receptor-mutated (EGFRm) lung cancer.

Study reveals vigorous physical activity correlates with lower rates of cognitive impairment in hypertensive patients.

Over the course of 15 years, epigenetic and transcriptional analysis of postmortem brain samples have revealed underlying molecular differences.

Data show women with poor cardiovascular health may have an increased risk of early signs of cognitive decline in midlife.

Daratumumab in combination with standard treatment regimens shows benefit in multiple myeloma.

The priority review of inavolisib is for treatment of patients with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation.

Quadruple therapies including immunotherapy agents show promise in treating patients with multiple myeloma.

Gender disparities among oncology health care professionals have significant consequences for both the physicians and the patients they treat.

Isatuximab is used in combination with bortezomib, lenalidomide, and dexamethanose.

UC Davis Health researchers uncover substantial treatment disparities and inequal access to autologous hematopoietic cell transplantation therapy among multiple myeloma patients.

Speakers at the 2024 Society of Pain and Palliative Care Virtual Conference discussed advanced treatment opportunities for patients with substance use disorder (SUD) and cancer-related pain.